Syqe’s CEO has told “Bloomberg” that the company expects approval in other countries with the US “the obvious target.”

Earlier this week, Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) announced that it had signed a cooperation and marketing agreement with the Israeli company Syqe Medical to market the world’s first cannabis inhaler.

Teva will start distributing the inhaler for pain treatment in Israel in 2017 and Syqe’s CEO Perry Davidson has told “Bloomberg” that it is seeking approval in other countries. “Israel is clearly just the start,” he said. “We expect to be approved for use in other countries in due course. The US, as the biggest medical cannabis market, is an obvious target.”

Read more on Globes here.